Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $906,000.

  • Foghorn Therapeutics' Capital Expenditures rose 29.41% to $22,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $838,000, marking a year-over-year increase of 253.59%. This contributed to the annual value of $906,000 for FY2024, which is 25.98% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Capital Expenditures stood at $906,000 for FY2024, which was down 25.98% from $1.2 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Capital Expenditures registered a high of $16.2 million during FY2020, and its lowest value of $906,000 during FY2024.
  • For the 3-year period, Foghorn Therapeutics' Capital Expenditures averaged around $1.1 million, with its median value being $1.2 million (2022).
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 1,571.80% in 2020, then slumped by 79.53% in 2021.
  • Over the past 5 years, Foghorn Therapeutics' Capital Expenditures (Yearly) stood at $16.2 million in 2020, then slumped by 79.53% to $3.3 million in 2021, then plummeted by 63.48% to $1.2 million in 2022, then climbed by 1.16% to $1.2 million in 2023, then declined by 25.98% to $906,000 in 2024.